These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 788750)

  • 21. Mineralocorticoid activity and the excretion of an oral potassium load in normal man.
    Hené RJ; Koomans HA; Rabelink AJ; Boer P; Dorhout Mees EJ
    Kidney Int; 1988 Nov; 34(5):697-703. PubMed ID: 3199680
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Detection and comparative evaluation of aldosterone antagonists in glucocorticoid-treated, adrenalectomized rats.
    Casals-Stenzel J; Buse M; Losert W
    Eur J Pharmacol; 1982 May; 80(1):37-45. PubMed ID: 7095004
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The urinary sodium: potassium ratio and response to diuretics in resistant oedema.
    Alexander WD; Branch RA; Levine DF; Hartog M
    Postgrad Med J; 1977 Mar; 53(617):117-21. PubMed ID: 323834
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antagonism of fludrocortisone by spironolactone and canrenone.
    Huston GJ; Turner P
    Br J Clin Pharmacol; 1976 Feb; 3(1):201-4. PubMed ID: 973942
    [No Abstract]   [Full Text] [Related]  

  • 25. Assessment of the antimineralocorticoid effect of RU 28318 in healthy men with induced exogenous and endogenous hypermineralocorticism.
    Ulmann A; Bertagna C; Le Go A; Husson JM; Tache A; Sassano P; Menard J; Corvol P
    Eur J Clin Pharmacol; 1985; 28(5):531-5. PubMed ID: 3899674
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of spironolactone and potassium canrenoate on cytosolic and nuclear androgen and estrogen receptors of rat liver.
    Francavilla A; Di Leo A; Eagon PK; Polimeno L; Guglielmi F; Fanizza G; Barone M; Starzl TE
    Gastroenterology; 1987 Oct; 93(4):681-6. PubMed ID: 3623016
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Relative potency of prorenoate potassium and spironolactone in attenuating diuretic induced hypokalaemia.
    McInnes GT; Harrison IR; Shelton JR; Perkins RM; Clarke JM
    Br J Clin Pharmacol; 1984 Aug; 18(2):169-74. PubMed ID: 6487456
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of spironolactone on diuresis and urine sodium and potassium excretion in healthy dogs.
    Jeunesse E; Woehrle F; Schneider M; Lefebvre HP
    J Vet Cardiol; 2007 Nov; 9(2):63-8. PubMed ID: 18024236
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Population Pharmacokinetic-Pharmacodynamic Model of Oral Fludrocortisone and Intravenous Hydrocortisone in Healthy Volunteers.
    Hamitouche N; Comets E; Ribot M; Alvarez JC; Bellissant E; Laviolle B
    AAPS J; 2017 May; 19(3):727-735. PubMed ID: 28083797
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In-vivo metabolites of spironolactone and potassium canrenoate: determination of potential anti-androgenic activity by a mouse kidney cytosol receptor assay.
    Armanini D; Karbowiak I; Goi A; Mantero F; Funder JW
    Clin Endocrinol (Oxf); 1985 Oct; 23(4):341-7. PubMed ID: 4064345
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of acute mineralocorticoid and glucocorticoid receptor blockade on the excretion of an acute potassium load in healthy humans.
    van Buren M; Boer P; Koomans HA
    J Clin Endocrinol Metab; 1993 Oct; 77(4):902-9. PubMed ID: 8408463
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Canrenone--the principal active metabolite of spironolactone?
    Ramsay LE; Shelton JR; Wilkinson D; Tidd MJ
    Br J Clin Pharmacol; 1976 Aug; 3(4):607-12. PubMed ID: 22216502
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Aldosterone antagonism studies in the rhesus monkey.
    Hofmann LM; Pedrera HA; Suleymamov OD
    J Pharmacol Exp Ther; 1977 Jul; 202(1):216-20. PubMed ID: 406381
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antagonism of spironolactone-induced natriuresis by aspirin in man.
    Tweeddale MG; Ogilvie RI
    N Engl J Med; 1973 Jul; 289(4):198-200. PubMed ID: 4576534
    [No Abstract]   [Full Text] [Related]  

  • 35. Relative potency of amiloride and spironolactone in healthy man.
    McInnes GT
    Clin Pharmacol Ther; 1982 Apr; 31(4):472-7. PubMed ID: 7060327
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Furosemide and bumetanide: a study of responses in normal English and German subjects.
    Branch RA; Read PR; Levine D; Elst EV; Shelton J; Rupp W; Ramsay LE
    Clin Pharmacol Ther; 1976 May; 19(5 Pt 1):538-45. PubMed ID: 1277709
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetics of spironolactone and potassium canrenoate in humans.
    Kojima K; Yamamoto K; Fujioka H; Kaneko H
    J Pharmacobiodyn; 1985 Mar; 8(3):161-6. PubMed ID: 4009408
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Progestogens with antimineralocorticoid activity.
    Losert W; Casals-Stenzel J; Buse M
    Arzneimittelforschung; 1985; 35(2):459-71. PubMed ID: 4039568
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effect of spironolactone on transport of Na+, K+ and H+. A microperfusion study in rat main submaxillary duct.
    Knauf H
    Eur J Clin Invest; 1976 Jan; 6(1):17-20. PubMed ID: 1253806
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Antiandrogenic effect of spirolactones: different mechanisms of action (author's transl)].
    Mahoudeau JA; Corvol P; Valcke JC; Menard J; Bricaire H
    Ann Endocrinol (Paris); 1976; 37(1):57-8. PubMed ID: 1015793
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.